Immunitas Therapeutics
Scott Rodig, M.D., Ph.D. is a Professor of Pathology at Harvard Medical School, a diagnostic and investigational pathologist at Brigham and Women’s Hospital, and the Director of the Center for Immuno-Oncology Tissue Biomarker Laboratory, at Dana-Farber Cancer Institute. His work is focused on analyzing the immune microenvironment of tumors through biomarker detection and cellular phenotype determination with an emphasis on discovering and exploring novel and translational approaches in immuno-oncology that improve diagnostic practice. Dr. Rodig earned his M.D. and Ph.D. from the Washington University School of Medicine in St. Louis. He completed his postdoctoral and residency training at Harvard Medical School and Brigham and Women’s Hospital, before joining the faculty at Harvard Medical School.
This person is not in the org chart
This person is not in any offices
Immunitas Therapeutics
Immunitas is an immuno-oncology therapeutics company advancing multiple programs to the clinic. Immunitas’ programs are derived from a cross-functional, highly integrated, single-cell genomics platform that enables rapid target identification and validation in parallel with antibody discovery and engineering.